La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SELLAS Life Sciences Gr a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SELLAS Life Sciences Gr..

SELLAS Life Sciences Gr (NASDAQ:SLS) Azioni, Catena delle Opzioni

SELLAS Life Sciences Gr

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Group Inc

Solaris Resources Inc

Solesence Inc

Solasto Corp

SELECT SANDS CORP ORD by Select Sands Corp.

Select Sands Corp

Solaris Resources Inc Ordinary Shares

News

Press Releases

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

Management

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

Small Cap

Opinion

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Health Care

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Earnings

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

AUTL

CATX

GOVX

INDP

ONCY

OSTX

TSX:ONC

ZAILF

ZLAB

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

C4 Therapeutics

Coherus Oncology

Caribou Biosciences

Elicio Therapeutics

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Forte Biosciences

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Genfit

Genelux

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vor Biopharma

Voyager Therapeutics, Inc. - Common Stock

Comments

SELLAS Life Sciences Gr

SELLAS Life Sciences Gr (SLS) Opzioni

SELLAS Life Sciences Gr (NASDAQ:SLS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO